HARVARD BIOSCIENCE INC
For the period ended Dec 31, 2025. Filed Mar 13, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 13, 2026
HBIO$9.26+1.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Comprehensive Loss
| HARVARD BIOSCIENCE, INC. | ||
|---|---|---|
| CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS | ||
| (In thousands) | ||
| Year Ended December 31, | ||
| 2025 | 2024 | |
| Net loss | $(56,700) | $(12,405) |
| Other comprehensive income (loss), net of tax: | ||
| Foreign currency translation adjustments | 3,248 | (1,405) |
| Defined benefit pension plans, net of tax benefit of $93 and $58, respectively | 651 | (175) |
| Derivative instruments qualifying as cash flow hedges, net of tax of $-0- | 99 | 100 |
| Other comprehensive income (loss) | 3,998 | (1,480) |
| Comprehensive loss | $(52,702) | $(13,885) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.